TITLE

Estimating the risk of rabies transmission to humans in the U.S.: a delphi analysis

AUTHOR(S)
Vaidya, Sagar A.; Manning, Susan E.; Dhankhar, Praveen; Meltzer, Martin I.; Rupprecht, Charles; Hull, Harry F.; Fishbein, Daniel B.
PUB. DATE
January 2010
SOURCE
BMC Public Health;2010, Vol. 10, p278
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: In the United States, the risk of rabies transmission to humans in most situations of possible exposure is unknown. Controlled studies on rabies are clearly not possible. Thus, the limited data on risk has led to the frequent administration of rabies post-exposure prophylaxis (PEP), often in inappropriate circumstances. Methods: We used the Delphi method to obtain an expert group consensus estimate of the risk of rabies transmission to humans in seven scenarios of potential rabies exposure. We also surveyed and discussed the merits of recommending rabies PEP for each scenario. Results: The median risk of rabies transmission without rabies PEP for a bite exposure by a skunk, bat, cat, and dog was estimated to be 0.05, 0.001, 0.001, and 0.00001, respectively. Rabies PEP was unanimously recommended in these scenarios. However, rabies PEP was overwhelmingly not recommended for non-bite exposures (e.g. dog licking hand but unavailable for subsequent testing), estimated to have less than 1 in 1,000,000 (0.000001) risk of transmission. Conclusions: Our results suggest that there are many common situations in which the risk of rabies transmission is so low that rabies PEP should not be recommended. These risk estimates also provide a key parameter for cost-effective models of human rabies prevention and can be used to educate health professionals about situation-specific administration of rabies PEP.
ACCESSION #
52038735

 

Related Articles

  • Oncologic Briefs.  // Dermatology Times;Jan2001, Vol. 22 Issue 1, p26 

    Reports global developments concerning skin diseases as of January 2001. Role of oral-oral contact plays in Kaposi sarcoma transmission; Accounts on the clinical trials for melanoma vaccines; Theoretical cause of melanoma.

  • Understanding the risk of rabies. Ainsworth, Steve // Practice Nurse;1/16/2009, Vol. 37 Issue 1, p10 

    The article discusses the risk of rabies in Great Britain. Classical rabies was eradicated from the country in 1922, but there have been at least 23 deaths among people infected with rabies since then. Rabies is a zoonotic disease caused by a virus. The virus infects both domestic and wild...

  • The vampire virus. Mims, Cedric // New Scientist;2/19/2011, Vol. 209 Issue 2800, p31 

    A letter to the editor is presented in response to an article by Paul Collins in the January 29, 2011 issue that was concerned with vampires.

  • Changing Patterns of Dengue Epidemiology and Implications for Clinical Management and Vaccines. Simmons, Cameron P.; Farrar, Jeremy // PLoS Medicine;Sep2009, Vol. 6 Issue 9, p1 

    The authors offer their perspectives on the varying patterns of dengue epidemiology and their impact on vaccination. The authors focus on the study "The Impact of the Demographic Transition on Dengue in Thailand," by Derek Cummings, S. Iamsirithaworn, J. T. Lessler, A. McDermott, and R....

  • Prezentari.  // Romanian Journal of Infectious Diseases;2012, Vol. 15 Issue 3, p121 

    No abstract available.

  • What kind of randomized trials do we need? Zwarenstein, Merrick; Treweek, Shaun // CMAJ: Canadian Medical Association Journal;5/12/2009, Vol. 180 Issue 10, p998 

    The article presents a reprint of the article regarding the use of the randomized trials (RCT), which appeared in the May 2009 issue of "Journal of Clinical Epidemiology." These randomized trials are embodied by the radically different attitudes of evaluating the pragmatic and explanatory...

  • Sample size calculation for multicentre efficacy trials of blood-stage malaria antigens. Bosomprah, Samuel // Malaria Journal;2013, Vol. 12 Issue 1, p1 

    Background: Sample size has increasingly become a prerequisite for grant approval. Study size calculations for multicentre trials are more complicated because these sites present different assumptions on incidence of disease expected in the control group; this then changes the mechanism of...

  • Defining HIV Susceptibility to New Antiretroviral Agents--Darunavir. Haubrich, Richard // Journal of Infectious Diseases;10/15/2007, Vol. 196 Issue 8, p1125 

    The article presents the author's comment on issues concerning decisions-making in selection of antiretroviral agents for treatment of human papillomavirus (HPV) disease in various clinical settings. The author appreciated the study by Yumi Mitsuya and colleagues on Darunavir resistance...

  • Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B. Gray, Elin Solomonovna; Meyers, Tammy; Gray, Glenda; Montefiori, David Charles; Morris, Lynn // PLoS Medicine;Jul2006, Vol. 3 Issue 7, pe255 

    Background: A Phase I clinical trial has been proposed that uses neutralising monoclonal antibodies (MAbs) as passive immunoprophylaxis to prevent mother-to-child transmission of HIV-1 in South Africa. To assess the suitability of such an approach, we determined the sensitivity of paediatric...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics